ZIM
PCVX icon

Zacks Investment Management’s Vaxcyte PCVX Stock Holding History

Zacks Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,250
Closed -$463K – 824
2025
Q2 		$463K Buy
14,250
+371
+3% +$12.2K ﹤0.01% 493
2025
Q1 		$524K Buy
13,879
+1,685
+14% +$135K ﹤0.01% 470
2024
Q4 		$998K Sell
12,194
-1,451
-11% -$144K 0.01% 423
2024
Q3 		$1.56M Buy
+13,645
New +$1.23M 0.01% 373

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Zacks Investment Management's PCVX Position: Q3 2025 in Review

Zacks Investment Management sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 14,250 shares — an estimated $463K sold.

Zacks Investment Management first reported a position in PCVX in Q3 2024 and held it in 4 quarters. The position peaked at $1.56M in Q3 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Zacks Investment Management reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Zacks Investment Management sold 14,250 Vaxcyte shares in Q3 2025, an estimated $463K.
  • Zacks Investment Management first reported a position in Vaxcyte in Q3 2024 and held it in 4 quarters.
  • Zacks Investment Management's Vaxcyte position peaked at $1.56M in Q3 2024.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Zacks Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.